Top Markets
Coin of the day
Fusion Antibodies plc Fusion Antibodies plc

Fusion Antibodies plc

FAB
株式のランク #20442
Fusion Antibodies plc, a contract research organization, engages in the... Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. It offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. The company serves pharmaceutical, biotech, and diagnostic companies. It has a collaboration partnership with Celonic AG. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.
株価
$0.16328419
時価総額
$204.14K
変化(1日)
4.35%
変化(1年)
102.45%
GB
取引 Fusion Antibodies plc (FAB)

カテゴリー

Fusion Antibodies plc(FAB)の収益
Sep 2025 時点の収益 TTM: $2.15M
Fusion Antibodies plc の最新の財務報告によると、現在の収益 (TTM) は $2.15M です。2024 年には $1.43M の収益があり、これは 2023 年の $3.58M と比較して 減少 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Fusion Antibodies plc の収益履歴(2013 ~ 2026)
各年末の収益
収益 変化
2026 (TTM) $2.15M -15.49%
2025 $2.54M 77.00%
2024 $1.43M -59.95%
2023 $3.58M -43.24%
2022 $6.31M 9.89%
2021 $5.74M 18.80%
2020 $4.83M 70.09%
2019 $2.84M -24.66%
2018 $3.77M 57.07%
2017 $2.40M 12.81%
2016 $2.13M 57.86%
2015 $1.35M 11.90%
2014 $1.20M 95.78%
2013 $615.46K 0.00%
同業他社の収益
企業 収益 収益の差
$48.44B 2,257,473.65%
DK
$12.04B 560,997.32%
US
$14.34B 668,407.67%
US
$9.08B 423,215.14%
BE
$5.49B 255,843.08%
NL